These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

240 related items for PubMed ID: 29240583

  • 21. KRAS mutations in traditional serrated adenomas from Korea herald an aggressive phenotype.
    Kim KM, Lee EJ, Kim YH, Chang DK, Odze RD.
    Am J Surg Pathol; 2010 May; 34(5):667-75. PubMed ID: 20305537
    [Abstract] [Full Text] [Related]

  • 22. Prognostic value of BRAF and KRAS mutation status in stage II and III microsatellite instable colon cancers.
    de Cuba EM, Snaebjornsson P, Heideman DA, van Grieken NC, Bosch LJ, Fijneman RJ, Belt E, Bril H, Stockmann HB, Hooijberg E, Punt CJ, Koopman M, Nagtegaal ID, Coupé VH, Carvalho B, Meijer GA.
    Int J Cancer; 2016 Mar 01; 138(5):1139-45. PubMed ID: 26376292
    [Abstract] [Full Text] [Related]

  • 23.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 24. Influence of anatomical subsite on the incidence of microsatellite instability, and KRAS and BRAF mutation rates in patients with colon carcinoma.
    Benedix F, Meyer F, Kube R, Kropf S, Kuester D, Lippert H, Roessner A, Krüger S.
    Pathol Res Pract; 2012 Oct 15; 208(10):592-7. PubMed ID: 22898351
    [Abstract] [Full Text] [Related]

  • 25. Next-Generation Sequencing of Matched Primary and Metastatic Rectal Adenocarcinomas Demonstrates Minimal Mutation Gain and Concordance to Colonic Adenocarcinomas.
    Crumley SM, Pepper KL, Phan AT, Olsen RJ, Schwartz MR, Portier BP.
    Arch Pathol Lab Med; 2016 Jun 15; 140(6):529-35. PubMed ID: 26536055
    [Abstract] [Full Text] [Related]

  • 26. Divergent oncogenic changes influence survival differences between colon and rectal adenocarcinomas.
    Kalady MF, Sanchez JA, Manilich E, Hammel J, Casey G, Church JM.
    Dis Colon Rectum; 2009 Jun 15; 52(6):1039-45. PubMed ID: 19581844
    [Abstract] [Full Text] [Related]

  • 27. A comprehensive study of nondysplastic and dysplastic serrated polyps of the vermiform appendix.
    Yantiss RK, Panczykowski A, Misdraji J, Hahn HP, Odze RD, Rennert H, Chen YT.
    Am J Surg Pathol; 2007 Nov 15; 31(11):1742-53. PubMed ID: 18059232
    [Abstract] [Full Text] [Related]

  • 28. EGFR and KRAS molecular genotyping for pulmonary carcinomas: Feasibility of a simple and rapid technique implementable in any department of pathology.
    Thomas De Montpréville V, Ghigna MR, Lacroix L, Lemoine A, Besse B, Mercier O, Fadel É, Dorfmuller P, Le Chevalier T, Institut d’Oncologie Thoracique.
    Pathol Res Pract; 2017 Jul 15; 213(7):793-798. PubMed ID: 28554746
    [Abstract] [Full Text] [Related]

  • 29. High frequency of KRAS mutation in early onset colorectal adenocarcinoma: implications for pathogenesis.
    Watson R, Liu TC, Ruzinova MB.
    Hum Pathol; 2016 Oct 15; 56():163-70. PubMed ID: 27346571
    [Abstract] [Full Text] [Related]

  • 30. Right Sided Colon Cancer as a Distinct Histopathological Subtype with Reduced Prognosis.
    Nitsche U, Stögbauer F, Späth C, Haller B, Wilhelm D, Friess H, Bader FG.
    Dig Surg; 2016 Oct 15; 33(2):157-63. PubMed ID: 26824772
    [Abstract] [Full Text] [Related]

  • 31. [Molecular analysis of sporadic colon cancer].
    Hurtado C, Wielandt AM, Zárate AJ, Kronberg U, Castro M, Yamagiwa K, Ito T, Eishi Y, Contreras L, López-Köstner F.
    Rev Med Chil; 2015 Mar 15; 143(3):310-9. PubMed ID: 26005817
    [Abstract] [Full Text] [Related]

  • 32. Molecular spectrum of somatic EGFR and KRAS gene mutations in non small cell lung carcinoma: determination of frequency, distribution pattern and identification of novel variations in Indian patients.
    Das BR, Bhaumik S, Ahmad F, Mandsaurwala A, Satam H.
    Pathol Oncol Res; 2015 Jul 15; 21(3):675-87. PubMed ID: 25637496
    [Abstract] [Full Text] [Related]

  • 33. KRAS mutations are associated with specific morphologic features in colon cancer.
    Gunal A, Hui P, Kilic S, Xu R, Jain D, Mitchell K, Robert M, Kenney B.
    J Clin Gastroenterol; 2013 Jul 15; 47(6):509-14. PubMed ID: 23090042
    [Abstract] [Full Text] [Related]

  • 34. The impact of KRAS mutation, microsatellite instability, and tumor laterality on the prognosis of nonmetastatic colon cancer.
    Tran CG, Goffredo P, Mott SL, Hart A, You YN, Vauthey JN, Weigel RJ, Hassan I.
    Surgery; 2022 Mar 15; 171(3):657-665. PubMed ID: 34865865
    [Abstract] [Full Text] [Related]

  • 35. Role of oncogenic pathways and KRAS/BRAF mutations in the behavior of colon adenocarcinoma in renal transplant patients.
    Revuelta I, Moya-Rull D, García-Herrera A, Rovira J, Ayala de la Peña F, Misiego A, Guzmán F, Oppenheimer F, Albanell J, Campistol JM.
    Transplantation; 2012 Mar 15; 93(5):509-17. PubMed ID: 22245873
    [Abstract] [Full Text] [Related]

  • 36. Stage III & IV colon and rectal cancers share a similar genetic profile: a review of the Oregon Colorectal Cancer Registry.
    Gawlick U, Lu KC, Douthit MA, Diggs BS, Schuff KG, Herzig DO, Tsikitis VL.
    Am J Surg; 2013 May 15; 205(5):608-12; discussion 612. PubMed ID: 23592171
    [Abstract] [Full Text] [Related]

  • 37. Epidermal growth factor receptor expression and KRAS and BRAF mutations: study of 39 sinonasal intestinal-type adenocarcinomas.
    Projetti F, Durand K, Chaunavel A, Léobon S, Lacorre S, Caire F, Bessède JP, Moreau JJ, Coulibaly B, Labrousse F.
    Hum Pathol; 2013 Oct 15; 44(10):2116-25. PubMed ID: 23791006
    [Abstract] [Full Text] [Related]

  • 38. Survival outcome according to KRAS mutation status in newly diagnosed patients with stage IV non-small cell lung cancer treated with platinum doublet chemotherapy.
    Brady AK, McNeill JD, Judy B, Bauml J, Evans TL, Cohen RB, Langer C, Vachani A, Aggarwal C.
    Oncotarget; 2015 Oct 06; 6(30):30287-94. PubMed ID: 26471290
    [Abstract] [Full Text] [Related]

  • 39. KRAS G>A mutation favors poor tumor differentiation but may not be associated with prognosis in patients with curatively resected duodenal adenocarcinoma.
    Fu T, Guzzetta AA, Jeschke J, Vatapalli R, Dave P, Hooker CM, Morgan R, Iacobuzio-Donahue CA, Liu B, Ahuja N.
    Int J Cancer; 2013 Jun 01; 132(11):2502-9. PubMed ID: 23065691
    [Abstract] [Full Text] [Related]

  • 40. Oxaliplatin, fluorouracil, and leucovorin with or without cetuximab in patients with resected stage III colon cancer (PETACC-8): an open-label, randomised phase 3 trial.
    Taieb J, Tabernero J, Mini E, Subtil F, Folprecht G, Van Laethem JL, Thaler J, Bridgewater J, Petersen LN, Blons H, Collette L, Van Cutsem E, Rougier P, Salazar R, Bedenne L, Emile JF, Laurent-Puig P, Lepage C, PETACC-8 Study Investigators.
    Lancet Oncol; 2014 Jul 01; 15(8):862-73. PubMed ID: 24928083
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 12.